Fig. 2From: Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in FranceHereditary angioedema (HAE) attacks (analyzed population). The analyzed population refers to all patients who had ≥ 1 quarterly follow-up visit (n = 69). aMedian (range) follow-up duration: 84.0 (61–182) days. bLast follow-up refers to either first or second follow-up visit, whichever occurred prior to the September 23, 2019 data freeze. cMedian (range) follow-up duration: 160 (63–232). Last follow-up is the patient’s last visit before September 23, 2019. ATU Authorization for Temporary Use, D day, SD standard deviationBack to article page